Clinical Trials | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
EBITDA before special items falls 1.3 percent to € 4.41 billion
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Subscribe To Our Newsletter & Stay Updated
